These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 12663600

  • 1. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
    van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM, DALI Study Group.
    Diabetes Care; 2003 Apr; 26(4):1216-23. PubMed ID: 12663600
    [Abstract] [Full Text] [Related]

  • 2. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
    Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, Anderson JL.
    Am Heart J; 2003 Dec; 146(6):1007-14. PubMed ID: 14660992
    [Abstract] [Full Text] [Related]

  • 3. Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease.
    Li J, Zhang L, Xie NZ, Deng B, Lv LX, Zheng LQ.
    Genet Mol Res; 2014 Mar 24; 13(1):2140-8. PubMed ID: 24737438
    [Abstract] [Full Text] [Related]

  • 4. Cholesteryl ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid-lowering diet in type 1 diabetes.
    Dullaart RP, Hoogenberg K, Riemens SC, Groener JE, van Tol A, Sluiter WJ, Stulp BK.
    Diabetes; 1997 Dec 24; 46(12):2082-7. PubMed ID: 9392500
    [Abstract] [Full Text] [Related]

  • 5. Cholesteryl ester transfer protein TaqIB polymorphism and its relation to parameters of the insulin resistance syndrome in an Austrian cohort.
    Weitgasser R, Galvan G, Malaimare L, Derflinger I, Hedegger M, Lang J, Iglseder B, Ladurner G, Paulweber B.
    Biomed Pharmacother; 2004 Dec 24; 58(10):619-27. PubMed ID: 15589073
    [Abstract] [Full Text] [Related]

  • 6. Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.
    Kotake H, Sekikawa A, Tokita Y, Ishigaki Y, Oikawa S.
    J Atheroscler Thromb; 2002 Dec 24; 9(5):207-12. PubMed ID: 12409629
    [Abstract] [Full Text] [Related]

  • 7. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.
    Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2000 May 24; 20(5):1323-9. PubMed ID: 10807749
    [Abstract] [Full Text] [Related]

  • 8. [Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
    Gao J, Cong HL, Mao YM, Liu Y, Zhang N, Chen Q, Liu T, Cui RZ.
    Zhonghua Yi Xue Za Zhi; 2013 Jul 23; 93(28):2195-9. PubMed ID: 24169327
    [Abstract] [Full Text] [Related]

  • 9. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
    Brousseau ME, O'Connor JJ, Ordovas JM, Collins D, Otvos JD, Massov T, McNamara JR, Rubins HB, Robins SJ, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2002 Jul 01; 22(7):1148-54. PubMed ID: 12117730
    [Abstract] [Full Text] [Related]

  • 10. An interaction between the TaqIB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high-density lipoprotein cholesterol levels in Turks.
    Hodoğlugil U, Williamson DW, Huang Y, Mahley RW.
    Clin Genet; 2005 Aug 01; 68(2):118-27. PubMed ID: 15996208
    [Abstract] [Full Text] [Related]

  • 11. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men.
    Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, Ridker PM.
    Atherosclerosis; 2002 Apr 01; 161(2):469-74. PubMed ID: 11888533
    [Abstract] [Full Text] [Related]

  • 12. Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
    Kolovou G, Kolovou V, Mihas C, Giannakopoulou V, Vasiliadis I, Boussoula E, Kollia A, Boutsikou M, Katsiki N, Mavrogeni S.
    Angiology; 2013 May 01; 64(4):266-72. PubMed ID: 22584245
    [Abstract] [Full Text] [Related]

  • 13. HDL cholesterol and TaqIB cholesteryl ester transfer protein gene polymorphism in renal transplant recipients.
    Radeau T, Vohl MC, Houde I, Lachance JG, Noël R, Després JP, Douville P, Bergeron J.
    Nephron; 2000 Apr 01; 84(4):333-41. PubMed ID: 10754410
    [Abstract] [Full Text] [Related]

  • 14. The frequency of the cholesteryl ester transfer protein-TaqI B2 allele is lower in African Americans than in Caucasians.
    Cuchel M, Wolfe ML, deLemos AS, Rader DJ.
    Atherosclerosis; 2002 Jul 01; 163(1):169-74. PubMed ID: 12048136
    [Abstract] [Full Text] [Related]

  • 15. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 2000 Jan 01; 20(1):189-97. PubMed ID: 10634817
    [Abstract] [Full Text] [Related]

  • 16. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
    Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ.
    N Engl J Med; 1998 Jan 08; 338(2):86-93. PubMed ID: 9420339
    [Abstract] [Full Text] [Related]

  • 17. A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels. Interaction with the TaqIB and -629C/A polymorphisms.
    Le Goff W, Guerin M, Nicaud V, Dachet C, Luc G, Arveiler D, Ruidavets JB, Evans A, Kee F, Morrison C, Chapman MJ, Thillet J.
    Atherosclerosis; 2002 Apr 08; 161(2):269-79. PubMed ID: 11888509
    [Abstract] [Full Text] [Related]

  • 18. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.
    van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.
    Curr Med Res Opin; 2009 Jan 08; 25(1):93-101. PubMed ID: 19210142
    [Abstract] [Full Text] [Related]

  • 19. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK.
    DNA Cell Biol; 2010 Oct 08; 29(10):629-37. PubMed ID: 20578904
    [Abstract] [Full Text] [Related]

  • 20. [Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
    Gao J, Cong HL, Mao YM, Liu Y, Zhang N, Chen Q, Liu T, Cui R.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct 08; 30(5):553-8. PubMed ID: 24078569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.